Abstract
Background: Traditional mistletoe (Viscum album L.) therapy has been frequently used in patients with cancer in Europe. The different mistletoe formulations available for oncological use are Iscador®, Iscucin®, AbnovaViscum®, and Lektinol®, as well as Helixor®, which may improve therapeutic outcomes following intravenous (i.v.) administration and therefore, is becoming more commonly used.
Method: I conducted an observational study in four different University Hospital Centers and the frequency of adverse drug reactions (ADRs) induced by the i.v. infusion of Helixor® was determined.
Result: of the 108 patients with gynecological cancer who received i.v. infusions of Helixor®, 10 (9.3%) reported mild ADRs, and no serious ADRs were reported.
Conclusion: Therefore, i.v. infusion of Helixor® was determined to be safe, and prospective efficacy studies are recommended.
Publisher
Granthaalayah Publications and Printers
Reference11 articles.
1. Melzer J, Iten F, Hostanska K, Saller R: Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forschende Komplementarmedizin 2009, 16(4):217-226.
2. Hajto T, Hostanska K, Saller R: Mistletoe therapy from the pharmacologic perspective. Forsch Komplementarmed 1999, 6(4):186-194.
3. Mansky PJ: Mistletoe and cancer: controversies and perspectives. Seminars in Oncology 2002, 29(6):589-594.
4. Hajto T, Hostanska K, Berki T, Palinkas L, Boldizsar F, Nemeth P: Oncopharmacological perspectives of a plant lectin (Viscum album Agglutinin-I): overview of recent results from in vitro experiments and in vivo animal models, and their possible relevance for clinical applications. Evidence-Based Complementary and Alternative Medicine: eCAM 2005, 2(1):59-67.
5. Steele ML, Axtner J, Happe A, Kroz M, Matthes H, Schad F: Safety of intravenous application of mistletoe (Viscum album L.) preparations in oncology: an observational study. Evidence-Based Complementary and Alternative Medicine: eCAM 2014, 2014:236310.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献